These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 24052490)

  • 21. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch.
    Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R
    BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
    Elshoff JP; Timmermann L; Schmid M; Arth C; Komenda M; Brunnert M; Bauer L
    Curr Med Res Opin; 2013 Dec; 29(12):1657-62. PubMed ID: 24006953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 29. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine.
    Beneš H; García-Borreguero D; Ferini-Strambi L; Schollmayer E; Fichtner A; Kohnen R
    Sleep Med; 2012 Jun; 13(6):589-97. PubMed ID: 22503658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.
    Nugroho AK; Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2004 May; 21(5):844-50. PubMed ID: 15180344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
    LeWitt PA; Lyons KE; Pahwa R;
    Neurology; 2007 Apr; 68(16):1262-7. PubMed ID: 17438216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal rotigotine in restless legs syndrome: impulse control disorders.
    Prescrire Int; 2014 Oct; 23(153):239. PubMed ID: 25964969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany.
    Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG
    Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists.
    Yasutaka Y; Fujioka S; Mishima T; Shibaguchi H; Tsuboi Y; Kamimura H
    Clin Neurol Neurosurg; 2020 Dec; 199():106266. PubMed ID: 33059317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
    Raison-Peyron N; Guillot B
    Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.